+

WO2008135661A3 - Utilisation de la citrulline pour pour le traitement de pathologies liees a une augmentation de la carbonylation des protéines - Google Patents

Utilisation de la citrulline pour pour le traitement de pathologies liees a une augmentation de la carbonylation des protéines Download PDF

Info

Publication number
WO2008135661A3
WO2008135661A3 PCT/FR2008/000379 FR2008000379W WO2008135661A3 WO 2008135661 A3 WO2008135661 A3 WO 2008135661A3 FR 2008000379 W FR2008000379 W FR 2008000379W WO 2008135661 A3 WO2008135661 A3 WO 2008135661A3
Authority
WO
WIPO (PCT)
Prior art keywords
citrulline
increase
treatment
protein carbonylation
conditions linked
Prior art date
Application number
PCT/FR2008/000379
Other languages
English (en)
Other versions
WO2008135661A2 (fr
Inventor
Christophe Moinard
Stephane Walrand
Yves Boirie
Luc Cynober
Original Assignee
Univ Paris Descartes
Christophe Moinard
Stephane Walrand
Yves Boirie
Luc Cynober
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Paris Descartes, Christophe Moinard, Stephane Walrand, Yves Boirie, Luc Cynober filed Critical Univ Paris Descartes
Priority to CN200880009440A priority Critical patent/CN101686919A/zh
Priority to EP08787826A priority patent/EP2136777A2/fr
Priority to CA002689608A priority patent/CA2689608A1/fr
Priority to JP2009554063A priority patent/JP2010522146A/ja
Priority to US12/532,299 priority patent/US20100093863A1/en
Publication of WO2008135661A2 publication Critical patent/WO2008135661A2/fr
Publication of WO2008135661A3 publication Critical patent/WO2008135661A3/fr
Priority to IL200830A priority patent/IL200830A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A61K8/442—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof substituted by amido group(s)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Polymers & Plastics (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Birds (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)

Abstract

La présente invention concerne l'utilisation de L-citrulline de formule (I) pour la préparation d'une composition cosmétique, d'une composition alimentaire ou nutraceutique ou d'une composition pharmaceutique destinée au traitement des pathologies liées à une augmentation de la carbonylation des protéines, notamment destinée au traitement des maladies neurodégénératives telles que les maladies d'Alzheimer ou de Parkinson.
PCT/FR2008/000379 2007-03-22 2008-03-20 Utilisation de la citrulline pour pour le traitement de pathologies liees a une augmentation de la carbonylation des protéines WO2008135661A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CN200880009440A CN101686919A (zh) 2007-03-22 2008-03-20 瓜氨酸用于治疗与蛋白质羰基化增加相关的病理学状态的用途
EP08787826A EP2136777A2 (fr) 2007-03-22 2008-03-20 Utilisation de la citrulline pour le traitement de pathologies liees a une augmentation de la carbonylation des proteines
CA002689608A CA2689608A1 (fr) 2007-03-22 2008-03-20 Utilisation de la citrulline pour la prevention de l`augmentation de la carbonylation des proteines et du traitement des pathologies qui en decoulent
JP2009554063A JP2010522146A (ja) 2007-03-22 2008-03-20 タンパク質のカルボニル化の増加の予防およびそれを原因とする病変の治療のためのシトルリンの使用
US12/532,299 US20100093863A1 (en) 2007-03-22 2008-03-20 Use of citrulline for preventing an increase in protein carbonylation and for treating diseases resulting therefrom
IL200830A IL200830A0 (en) 2007-03-22 2009-09-09 Use of citrulline for preventing an increase in protein carbonylation and for treating diseases resulting therefrom

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0702090 2007-03-22
FR0702090A FR2913885B1 (fr) 2007-03-22 2007-03-22 Utilisation de la citrulline pour le traitement des pathologies liees a une augmentation de la carbonylation des proteines

Publications (2)

Publication Number Publication Date
WO2008135661A2 WO2008135661A2 (fr) 2008-11-13
WO2008135661A3 true WO2008135661A3 (fr) 2009-01-15

Family

ID=38561836

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2008/000379 WO2008135661A2 (fr) 2007-03-22 2008-03-20 Utilisation de la citrulline pour pour le traitement de pathologies liees a une augmentation de la carbonylation des protéines

Country Status (8)

Country Link
US (1) US20100093863A1 (fr)
EP (1) EP2136777A2 (fr)
JP (1) JP2010522146A (fr)
CN (1) CN101686919A (fr)
CA (1) CA2689608A1 (fr)
FR (1) FR2913885B1 (fr)
IL (1) IL200830A0 (fr)
WO (1) WO2008135661A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102600260A (zh) * 2010-12-24 2012-07-25 漆又毛 一种氨基酸和提取物组合物防治老年性痴呆的药物用途
AU2012231351B2 (en) * 2011-03-18 2016-03-10 Société des Produits Nestlé S.A. Compositions and methods useful for ameliorating age related maladies
JP2014512371A (ja) * 2011-04-18 2014-05-22 ネステク ソシエテ アノニム α−ＨＩＣＡ及びシトルリンを含有する栄養組成物
US20140235735A1 (en) * 2013-02-15 2014-08-21 Mediterranean Institute For Life Sciences Protein Damage in Aging and Age-Related Diseases
CN106137782A (zh) * 2015-04-22 2016-11-23 捷通国际有限公司 包含青藤碱的局部组合物及用于抑制蛋白羰基化的方法
JP7220838B2 (ja) * 2015-09-29 2023-02-13 学校法人北里研究所 経口組成物
CN105147684B (zh) * 2015-09-30 2017-12-12 暨南大学 胡椒碱在制备防治败血症药物中的应用
KR102531118B1 (ko) * 2023-01-05 2023-05-11 주식회사 마이크로엑스 패혈증의 예방, 개선 또는 치료용 조성물

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2691359A1 (fr) * 1992-05-20 1993-11-26 Krempf Michel Nouvelle application thérapeutique du Malate de 1-Citrulline.
FR2766712A1 (fr) * 1997-08-01 1999-02-05 Aguettant Lab Composition de preference solution antioxydante et medicaments en faisant application
DE19929993A1 (de) * 1999-06-30 2001-01-11 Sueddeutsche Kalkstickstoff Kreatin-alpha-ketoglutarate, Verfahren zu ihrer Herstellung und ihre Verwendung
US20010056068A1 (en) * 1998-03-04 2001-12-27 Kristof Chwalisz Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives
US20020143060A1 (en) * 2001-02-05 2002-10-03 Takayuki Kohchi Active oxygen scavenging composition including citrulline
US20030083380A1 (en) * 1986-12-23 2003-05-01 Yu Ruey J. Method of using hydroxycarboxylic acids or related compounds for treating skin changes asociated with intrinsic and extrinsic aging
FR2853210A1 (fr) * 2003-04-02 2004-10-08 Neolait Sas Composition activateur de la digestion
US20040235953A1 (en) * 1999-06-01 2004-11-25 Vanderbilt University Therapeutic methods employing nitric oxide precursors
EP1495755A1 (fr) * 2003-07-08 2005-01-12 Laboratoires Biocodex Utilisation de la citrulline dans la fabrication d'un médicament pour le traitement de l'insuffisance intestinale
WO2005115371A1 (fr) * 2004-04-29 2005-12-08 Universite Rene Descartes-Paris 5 Compositions pharmaceutiques pour la prevention et le traitement de l'atherosclerose
US20060046982A1 (en) * 2004-08-26 2006-03-02 Waugh William H Orthomolecular medical use of L-citrulline for capillary endothelial protection and adjacent cell protection in neurodegenerative disease
WO2006036634A2 (fr) * 2004-09-23 2006-04-06 Yu Ruey J Administration systemique d'acides amines et d'acides n-acetylamines therapeutiques
WO2006131054A1 (fr) * 2005-06-04 2006-12-14 Zichun Li Compositions ophtalmologiques pharmaceutiques chinoises se présentant sous forme de solutions, onguents et pilules pour la reconstruction des signes du vieillissement
EP1752156A1 (fr) * 2004-04-30 2007-02-14 National University Corporation Nara Institute of Science and Technology Éliminateur d'oxygène actif et hydratnant contenant de l'extrait de melon sauvage
WO2008049984A2 (fr) * 2006-10-17 2008-05-02 Universite Rene Descartes-Paris 5 Utilisation de la citrulline pour le traitement des etats de denutrition

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4341000A1 (de) * 1993-12-02 1995-06-08 Beiersdorf Ag Verwendung von L-Arginin, L-Ornithin oder L-Citrullin und topischen Zubereitungen mit diesen Stoffen
NL1014380C2 (nl) * 2000-02-14 2001-08-15 Friesland Brands Bv Darmwandversterkend voedingsmiddel.
US20040087490A1 (en) * 2002-09-20 2004-05-06 Troup John P. Nutritional compositions
CA2530863A1 (fr) * 2003-07-01 2005-01-13 Essentys Ab Utilisation d'acide alpha-cetoglutarique pour le traitement d'etat de malnutrition ou de taux eleve de glucose
JP3878612B2 (ja) * 2004-03-01 2007-02-07 ピアス株式会社 活性酸素抑制用の組成物と、その組成物を配合する皮膚外用剤及び化粧料
JP4255432B2 (ja) * 2004-10-28 2009-04-15 株式会社ファンケル 異常蛋白質除去用組成物
WO2007023931A1 (fr) * 2005-08-25 2007-03-01 Kyowa Hakko Kogyo Co., Ltd. Préparation pour la prévention de l'augmentation de la concentration sanguine en alcool
MX2008012723A (es) * 2006-04-04 2008-10-14 Nestec Sa Tratamientos que usan citrulina.

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030083380A1 (en) * 1986-12-23 2003-05-01 Yu Ruey J. Method of using hydroxycarboxylic acids or related compounds for treating skin changes asociated with intrinsic and extrinsic aging
FR2691359A1 (fr) * 1992-05-20 1993-11-26 Krempf Michel Nouvelle application thérapeutique du Malate de 1-Citrulline.
FR2766712A1 (fr) * 1997-08-01 1999-02-05 Aguettant Lab Composition de preference solution antioxydante et medicaments en faisant application
US20010056068A1 (en) * 1998-03-04 2001-12-27 Kristof Chwalisz Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives
US20040235953A1 (en) * 1999-06-01 2004-11-25 Vanderbilt University Therapeutic methods employing nitric oxide precursors
DE19929993A1 (de) * 1999-06-30 2001-01-11 Sueddeutsche Kalkstickstoff Kreatin-alpha-ketoglutarate, Verfahren zu ihrer Herstellung und ihre Verwendung
US20020143060A1 (en) * 2001-02-05 2002-10-03 Takayuki Kohchi Active oxygen scavenging composition including citrulline
FR2853210A1 (fr) * 2003-04-02 2004-10-08 Neolait Sas Composition activateur de la digestion
EP1495755A1 (fr) * 2003-07-08 2005-01-12 Laboratoires Biocodex Utilisation de la citrulline dans la fabrication d'un médicament pour le traitement de l'insuffisance intestinale
WO2005115371A1 (fr) * 2004-04-29 2005-12-08 Universite Rene Descartes-Paris 5 Compositions pharmaceutiques pour la prevention et le traitement de l'atherosclerose
EP1752156A1 (fr) * 2004-04-30 2007-02-14 National University Corporation Nara Institute of Science and Technology Éliminateur d'oxygène actif et hydratnant contenant de l'extrait de melon sauvage
US20060046982A1 (en) * 2004-08-26 2006-03-02 Waugh William H Orthomolecular medical use of L-citrulline for capillary endothelial protection and adjacent cell protection in neurodegenerative disease
WO2006036634A2 (fr) * 2004-09-23 2006-04-06 Yu Ruey J Administration systemique d'acides amines et d'acides n-acetylamines therapeutiques
WO2006131054A1 (fr) * 2005-06-04 2006-12-14 Zichun Li Compositions ophtalmologiques pharmaceutiques chinoises se présentant sous forme de solutions, onguents et pilules pour la reconstruction des signes du vieillissement
WO2008049984A2 (fr) * 2006-10-17 2008-05-02 Universite Rene Descartes-Paris 5 Utilisation de la citrulline pour le traitement des etats de denutrition

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DALLE-DONNE ISABELLA ET AL: "Protein carbonylation, cellular dysfunction, and disease progression", JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, vol. 10, no. 2, April 2006 (2006-04-01), pages 389 - 406, XP009091325, ISSN: 1582-1838 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; March 2006 (2006-03-01), RASMUSEN CAROLE ET AL: "Effects of L-arginine/citrulline-simvastatin (SIM) association on nitric oxide production in endothelial cells", XP002456360, Database accession no. PREV200600343214 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 15 December 2006 (2006-12-15), LI, ZICHUN: "Chinese medicine mixtures of ophthalmic formulations for antiaging uses", XP002456361, retrieved from STN Database accession no. 2006:1310642 *
FASEB JOURNAL, vol. 20, no. 4, Part 1, March 2006 (2006-03-01), EXPERIMENTAL BIOLOGY 2006 MEETING; SAN FRANCISCO, CA, USA; APRIL 01 05, 2006, pages A148, ISSN: 0892-6638 *
NYSTROM THOMAS: "Role of oxidative carbonylation in protein quality control and senescence", EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 24, no. 7, April 2005 (2005-04-01), pages 1311 - 1317, XP002456358, ISSN: 0261-4189 *
RENKE JOANNA ET AL: "Protein carbonyl groups' content as a useful clinical marker of antioxidant barrier impairment in plasma of children with juvenile chronic arthritis", FREE RADICAL BIOLOGY AND MEDICINE, vol. 29, no. 2, 15 July 2000 (2000-07-15), pages 101 - 104, XP002456359, ISSN: 0891-5849 *

Also Published As

Publication number Publication date
EP2136777A2 (fr) 2009-12-30
CN101686919A (zh) 2010-03-31
IL200830A0 (en) 2010-05-17
CA2689608A1 (fr) 2008-11-13
FR2913885B1 (fr) 2012-07-20
JP2010522146A (ja) 2010-07-01
WO2008135661A2 (fr) 2008-11-13
FR2913885A1 (fr) 2008-09-26
US20100093863A1 (en) 2010-04-15

Similar Documents

Publication Publication Date Title
WO2012080727A3 (fr) Inhibiteurs de caséine kinase 1 delta (ck1delta)
WO2008135661A3 (fr) Utilisation de la citrulline pour pour le traitement de pathologies liees a une augmentation de la carbonylation des protéines
WO2010066684A3 (fr) Inhibiteurs pyridyloxyindoles de vegf-r2 et utilisation thérapeutique de ceux-ci
SG179120A1 (en) Novel compounds
WO2010048332A3 (fr) Composés de traitement de maladies et troubles ophtalmiques
WO2007038459A3 (fr) Composes de carboxyamine et leurs methodes d'utilisation
WO2009130198A3 (fr) Facteur ix de coagulation humain hyperglycosylé
EP2151435A4 (fr) Composition pharmaceutique pour le traitement de la maladie d'alzheimer
WO2009153496A3 (fr) Composes agonistes ppar, preparation et utilisations pour le traitement du diabete et/ou des dyslipidemies
WO2011044506A3 (fr) Composés sulfonés et leurs procédés de fabrication et d'utilisation
WO2007067495A3 (fr) Mésylate de promédicament de lévodopa, compositions comprenant celui-ci, et utilisations de celui-ci
BRPI0911874A2 (pt) composições combinadas para o tratamento da doença de alzheimer e doenças relacionadas com zonisamida e acamprosato
WO2006078576A3 (fr) Inhibiteurs de la $g(b)-secretase d'aminomethyle dans le traitement de la maladie d'alzheimer
MY173699A (en) Novel compounds for the treatment of diseases associated with amyloid of amyloid-like proteins
MY179527A (en) Catecholamine derivatives useful for the treatment of parkinson's disease
MX2009010407A (es) Derivados fluorados de deferiprona.
EP4364801A3 (fr) Dosage optimisé de diaminophénothiazines dans des populations
UA101393C2 (ru) КОМПОЗИЦИИ И ПРИМЕНЕНИЕ ПРОИЗВОДНЫХ ТРИАЗОЛА ДЛЯ ЛЕЧЕНИЯ β-АМИЛОИДОЗОВ И СИНУКЛЕИНОПАТИЙ
WO2007125331A3 (fr) Amino-éthyl-amino-aryles (aeaa) et leurs applications
WO2010067078A3 (fr) Sels de xanthylium disubstitués en 3 et 6
HK1104280A1 (en) Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases
WO2010000089A8 (fr) Stat3 et tyk2 en tant que cibles de médicaments pour maladies neurodégénératives
UA88634C2 (en) Quaternized quinuclidine esters
WO2010129665A3 (fr) Pyrimidine-2,4,6-triones destinée à être utilisée pour le traitement d'une sclérose latérale amyotrophe
WO2009053628A3 (fr) Nouveaux composes, préparation et utilisations

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880009440.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08787826

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008787826

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200830

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2689608

Country of ref document: CA

Ref document number: 2009554063

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12532299

Country of ref document: US

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载